Liraglutide

01 What is Liraglutide?

Before Semaglutide became a cultural phenomenon, Liraglutide (brand name Saxenda for weight loss, Victoza for diabetes) was the original GLP-1 receptor agonist approved for obesity. It has been around since 2014 for weight management, which means we have nearly a decade of real-world safety data — something the newer agents cannot yet claim. Liraglutide produces more modest weight loss than Semaglutide (about 8-10% vs 15-17%), and it requires daily rather than weekly injections. So why does it still matter? First, some people tolerate it better than Semaglutide — the GI side effects can be less intense. Second, the daily dosing allows for more granular dose adjustment. Third, we have long-term cardiovascular outcome data (LEADER trial) showing it reduces heart attacks and strokes in diabetic patients. For the biohacking community, Liraglutide is often the 'starter' GLP-1 — lower commitment, well-understood side effect profile, and easier to titrate. If you respond well, you might eventually switch to weekly Semaglutide for convenience. If you are cautious about newer agents, Liraglutide offers a proven track record.

02 How Does It Work?

Liraglutide is a GLP-1 receptor agonist with 97% homology to native human GLP-1. It binds GLP-1 receptors in: 1. Hypothalamus: Reduces appetite and increases satiety signalling. 2. Stomach: Slows gastric emptying (feel full longer after meals). 3. Pancreas: Enhances glucose-dependent insulin secretion, suppresses glucagon. 4. Heart: Provides cardiovascular protection through multiple mechanisms. Compared to native GLP-1 (which has a half-life of 2 minutes), Liraglutide's fatty acid chain allows albumin binding, extending half-life to 13 hours — hence daily dosing.

03 What Does The Research Say?

SCALE trials (obesity): 3,731 participants. Mean weight loss 8-10% over 56 weeks at 3.0mg daily. About 63% of participants achieved 5%+ weight loss (vs 27% placebo). Sustained over 3 years with continued use. LEADER trial (cardiovascular): 9,340 diabetic patients. 13% reduction in major cardiovascular events (heart attack, stroke, CV death). First GLP-1 to demonstrate CV benefit. Long-term safety: Extensive post-marketing data since 2010 (diabetes) and 2014 (obesity). Well-characterised safety profile. No unexpected long-term signals have emerged.

04 Reported Dosages

Obesity (Saxenda): Start at 0.6mg daily subcutaneous, escalate by 0.6mg weekly until reaching 3.0mg daily maintenance. Diabetes (Victoza): 0.6-1.8mg daily. Daily injection (unlike weekly Semaglutide). Inject in abdomen, thigh, or upper arm. Rotate sites. Pen device — no reconstitution needed. Available by prescription. Discuss with your doctor whether GLP-1 therapy is appropriate for your situation.

05 Side Effects & Risks

Nausea (40% initially, improves over weeks), constipation, diarrhoea, headache, decreased appetite. Most GI side effects resolve within 4-8 weeks as the body adapts. Rare but serious: pancreatitis (0.4%), gallbladder disease (especially with rapid weight loss), thyroid C-cell tumours (theoretical — seen in rodents at very high doses, not confirmed in humans). Contraindicated in personal/family history of medullary thyroid carcinoma.

06 Legal Status